



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Masahiro YATAKE
Serial No.: 09/909,417 Group No.: 1714
Filed: July 19, 2001 Examiner.: Callie E. Shosho
For: SACCHARIDE-ALKYLENEOXY DERIVATIVE AND INK

RECEIVED
OCT 21 2003
TC 1700

Attorney Docket No.: U 013559-6

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 17 2003
TECHNOLOGY CENTER

SUPPLEMENTAL RESPONSE

Further to Applicant's Amendment dated July 24, 2003, and in supplemental response to the Official Action of January 24, 2003, Applicant submits herewith a Declaration Under 37 CFR 1.132 which describes the results of experimentation that

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

- ☒ with sufficient postage as first class mail.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: October 9, 2003

37 C.F.R. 1.10*
☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

Signature

CLIFFORD J. MASS
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.


shows the unexpectedly advantageous results that can be achieved with the claimed invention. A signed declaration will be submitted shortly.

As discussed in the Amendment dated July 24, 2003 (see paragraph bridging pages 5 and 6), the claims require both the recited saccharide derivative comprising the compound represented by formula (1) and one or more of the recited C₃-C₁₂ saccharides, whereas the references at most teach the substitution of the saccharides described in Sano et al for the derivative described in the primary references. Nevertheless, even assuming for the sake of argument that the references provided a motivation to combine the recited derivative of formula (1) and the recited saccharide in a single composition and set forth a *prima facie* case of alleged obviousness, it is respectfully submitted that the evidence in the declaration shows unexpected results that would be sufficient to rebut such *prima facie* case.

The declaration shows at Table A that the ink compositions comprising both the compound of formula (1) and the recited saccharides (Test Examples 4-6) performed better in the nozzle clogging recovery test described in the declaration than did the ink compositions comprising one of these components singly (Test Examples 1-3). There is nothing in the cited references which would show or suggest these results wherefore it is respectfully submitted that the results must be considered to have been unexpected and sufficient to overcome any alleged case of *prima facie* obviousness set forth by the references.

In view of the above, an early and favorable reconsideration of the application
is again respectfully requested.

Respectfully submitted,



CLIFFORD J. MASS
LADAS & PARRY
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO.30,086(212)708-1890